NCT05357950View on ClinicalTrials.gov

A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

May 31, 2022

Primary Completion Date

November 2, 2023

Study Completion Date

November 4, 2024

Conditions
Amyotrophic Lateral SclerosisALS
Interventions
DRUG

PrimeC

Ciprofloxacin and celecoxib combination extended release formulation

DRUG

Placebo

Placebo matches active drug in size, color and taste

Trial Locations (4)

Unknown

Lawson Health Research Institute, London

Tel Aviv Sourasky Medical Center, Tel Aviv

IRCCS Istituti clinici Maugeri, Milan

A.O.U. Citta della Salute e della Scienza di Torino, Torino

Sponsors
All Listed Sponsors
lead

NeuroSense Therapeutics Ltd.

INDUSTRY

NCT05357950 - A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS | Biotech Hunter | Biotech Hunter